RANI - NASDAQ

Rani Therapeutics Holdings, Inc.

RANI·NASDAQ

$0.88

+2.9%

HealthcareBiotechnology

Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics. The company develops the RaniPill capsule, a platform that is intended to replace subcutaneous or IV injection of biologics with oral dosing. Its product pipeline includes RT-101, an octreotide, which has completed Phase I clinical trial for the treatment of neuroendocrine tumors and acromegaly; RT-105, an anti-TNF-alpha antibody to treat psoriatic arthritis; RT-102, a parathyroid hormone that is in preclinical studies for the treatment of osteoporosis; RT-109, a human growth hormone to treat growth hormone deficiency; RT-110, a parathyroid hormone for the treatment of hypoparathyroidism; and RT-106, a basal insulin for the treatment of type 2 diabetes. The company was incorporated in 2012 and is headquartered in San Jose, California.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$57.16M

EPS-0.4500

P/E Ratio-1.94

Earnings Date08/06/2026

rani

Interest Expense

Last Annual Value

2.89M

3-Year CAGR

39%

5-Year CAGR

88%

10-Year CAGR

76%

Adjust for Inflation

Rani Therapeutics Holdings, Inc. Competitors Analysis of Interest Expense

RANI · NASDAQ

Company	Interest Expense	CAGR 3Y	CAGR 5Y	CAGR 10Y
Rani Therapeutics Holdings, Inc. NASDAQ:RANI	2.89M	-17.2%	44.1%	N/A
Corbus Pharmaceuticals Holdings, Inc. NASDAQ:CRBP	0.00	N/A	N/A	N/A
Elicio Therapeutics, Inc. NASDAQ:ELTX	1.13M	2.3%	5.3%	N/A
Tonix Pharmaceuticals Holding Corp. NASDAQ:TNXP	89.00K	N/A	N/A	N/A
Annovis Bio, Inc. NYSE:ANVS	0.00	N/A	N/A	N/A
AN2 Therapeutics, Inc. NASDAQ:ANTX	0.00	N/A	N/A	N/A
Verrica Pharmaceuticals Inc. NASDAQ:VRCA	7.74M	25.0%	12.5%	N/A
X4 Pharmaceuticals, Inc. NASDAQ:XFOR	8.88M	15.4%	19.5%	13.4%
Applied Therapeutics, Inc. NASDAQ:APLT	0.00	N/A	N/A	N/A
Cardiff Oncology, Inc. NASDAQ:CRDF	0.00	N/A	N/A	N/A
Sangamo Therapeutics, Inc. NASDAQ:SGMO	0.00	N/A	N/A	N/A

Rani Therapeutics Holdings, Inc. Fair Value Envelope

RANI · NASDAQ

Our analysis suggests that RANI has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $0.8751, this represents a potential HIDDEN relative to our calculated worth for Rani Therapeutics Holdings, Inc..

HIDDEN

Intrinsic Value

Current Price: $0.8751

Related Guides

Blog Categories

Continue your RANI research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.